Literature DB >> 18821942

Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy.

J C Gaardbo1, S D Nielsen, S J Vedel, A K Ersbøll, L Harritshøj, L P Ryder, J O Nielsen, L Kolte.   

Abstract

Infection with human immunodeficiency virus (HIV) causes a dysregulation of the immune system. This is caused by HIV-specific as well as non-specific mechanisms and has not been explained fully. In particular, knowledge is lacking about the potential role of host-mediated immunosuppressive mechanisms. During recent years it has become evident that a subpopulation of T cells [T regulatory (T(regs))] play a major role in sustaining tolerance to self-antigens. To investigate the influence of initiation of highly active anti-retroviral therapy (HAART) on the T(reg) level in HIV-infected patients we have conducted a prospective study enrolling treatment-naive HIV-infected patients just prior to starting treatment with HAART, measuring levels of T(regs) by flow cytometry and mRNA expression of forkhead box P3 (FoxP3) at weeks 0, 4, 12 and 24 of treatment. In this prospective study neither the percentage of CD4(+)CD25(high+) nor the expression of FoxP3 changed significantly during 24 weeks of HAART. Furthermore, HIV patients have higher T(regs) measured as percentages of CD4(+)CD25(high+) cells paralleled by higher levels of FoxP3 compared with healthy controls. The elevated level of T(regs) was found to be independent of both immunological and virological status, indicating that initiation of HAART has minor effects on the T(reg) level in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821942      PMCID: PMC2561082          DOI: 10.1111/j.1365-2249.2008.03725.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

Review 1.  The impact of antiretroviral therapy on AIDS and survival.

Authors:  Jens D Lundgren; Amanda Mocroft
Journal:  J HIV Ther       Date:  2006-06

2.  Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART.

Authors:  Hans-Jörg Epple; Christoph Loddenkemper; Desirée Kunkel; Hanno Tröger; Jochen Maul; Verena Moos; Erika Berg; Reiner Ullrich; Jörg-Dieter Schulzke; Harald Stein; Rainer Duchmann; Martin Zeitz; Thomas Schneider
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 4.  Thymic regulatory T cells.

Authors:  Enrico Maggi; Lorenzo Cosmi; Francesco Liotta; Paola Romagnani; Sergio Romagnani; Francesco Annunziato
Journal:  Autoimmun Rev       Date:  2005-11       Impact factor: 9.754

5.  Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients.

Authors:  Sachi Tsunemi; Tsuyoshi Iwasaki; Takehito Imado; Satoshi Higasa; Eizo Kakishita; Takuma Shirasaka; Hajime Sano
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

6.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

7.  Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy.

Authors:  Andrew Y-F Lim; Patricia Price; Manfred W Beilharz; Martyn A French
Journal:  Immunol Cell Biol       Date:  2006-09-05       Impact factor: 5.126

8.  The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.

Authors:  Jan Andersson; Adriano Boasso; Jakob Nilsson; Rui Zhang; Norah J Shire; Stefan Lindback; Gene M Shearer; Claire A Chougnet
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

9.  Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients.

Authors:  Laurence Weiss; Vladimira Donkova-Petrini; Laure Caccavelli; Michèle Balbo; Cédric Carbonneil; Yves Levy
Journal:  Blood       Date:  2004-07-22       Impact factor: 22.113

10.  Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.

Authors:  Andrew Lim; Dino Tan; Patricia Price; Adeeba Kamarulzaman; Hong-Yien Tan; Ian James; Martyn A French
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

View more
  24 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients.

Authors:  R J Argüello; J Balbaryski; G Barboni; M Candi; E Gaddi; S Laucella
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

Review 3.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

4.  Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.

Authors:  Mathias Lichterfeld; Rajesh T Gandhi; Rachel P Simmons; Theresa Flynn; Amy Sbrolla; Xu G Yu; Nesli Basgoz; Stanley Mui; Katie Williams; Hendrik Streeck; Nicole Burgett-Yandow; Gilbert Roy; Michel Janssens; Louise Pedneault; Pierre Vandepapelière; Marguerite Koutsoukos; Marie-Ange Demoitié; Patricia Bourguignon; Lisa McNally; Gerald Voss; Marcus Altfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

5.  Phenotypic characterization of regulatory T cells from antiretroviral-naive HIV-1-infected people.

Authors:  Georgia N Ambada; Claudine E Ntsama; Nadesh N Nji; Loveline N Ngu; Carole N Sake; Abel Lissom; Flaurent T Tchouangeu; Jules Tchadji; Martin Sosso; François-Xavier Etoa; Godwin W Nchinda
Journal:  Immunology       Date:  2017-05-18       Impact factor: 7.397

6.  Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques.

Authors:  Jeffy George; Egidio Brocca Cofano; Elizabeth Lybarger; Mark Louder; Bernard A P Lafont; John R Mascola; Marjorie Robert-Guroff; Joseph J Mattapallil
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-17       Impact factor: 2.205

7.  Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.

Authors:  J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity.

Authors:  Melinda S Suchard; Elizabeth Mayne; Victoria A Green; Sharon Shalekoff; Samantha L Donninger; Wendy S Stevens; Clive M Gray; Caroline T Tiemessen
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

Review 9.  Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.

Authors:  Emily S Ford; Camille E Puronen; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

10.  Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs.

Authors:  L Kolte; J C Gaardbo; K Skogstrand; L P Ryder; A K Ersbøll; S D Nielsen
Journal:  Clin Exp Immunol       Date:  2008-11-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.